Oncology Institute - Public Comps and Valuation Multiples

Oncology Institute Overview

About Oncology Institute

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.

Founded

2007

HQ

Employees

825

Website

theoncologyinstitute.com

Sectors

Long-Term Care

Financials

LTM Revenue $454M

LTM EBITDA -$16.5M

EV

$395M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Oncology Institute Financials

As of September 2025, Oncology Institute reported last 12-month revenue of $454M and EBITDA of -$16.5M.

In the same period, Oncology Institute generated $69.3M in LTM gross profit and -$56.2M in net income.

See Oncology Institute valuation multiples based on analyst estimates

Oncology Institute P&L

In the most recent fiscal year, Oncology Institute reported revenue of $393M and EBITDA of -$50.9M.

Oncology Institute expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Oncology Institute valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$454M	XXX	$393M	XXX	XXX	XXX
Gross Profit	$69.3M	XXX	$54.0M	XXX	XXX	XXX
Gross Margin	15%	XXX	14%	XXX	XXX	XXX
EBITDA	-$16.5M	XXX	-$50.9M	XXX	XXX	XXX
EBITDA Margin	-4%	XXX	-13%	XXX	XXX	XXX
EBIT	-$42.0M	XXX	-$60.1M	XXX	XXX	XXX
EBIT Margin	-9%	XXX	-15%	XXX	XXX	XXX
Net Profit	-$56.2M	XXX	-$64.7M	XXX	XXX	XXX
Net Margin	-12%	XXX	-16%	XXX	XXX	XXX
Net Debt	XXX	XXX	$43.5M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Oncology Institute including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $454M. EBITDA for the last twelve months was -$16.5M. In the most recent fiscal year, Oncology Institute achieved $393M in revenue and -$50.9M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$454M	Analyst estimates available to subscribers	$393M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$69.3M	Analyst estimates available to subscribers	$54.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	15.3% gross margin	Analyst estimates available to subscribers	13.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$16.5M	Analyst estimates available to subscribers	-$50.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-3.6% EBITDA margin	Analyst estimates available to subscribers	-12.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$42.0M	Analyst estimates available to subscribers	-$60.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-9.2% EBIT margin	Analyst estimates available to subscribers	-15.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$56.2M	Analyst estimates available to subscribers	-$64.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-12.4% net profit margin	Analyst estimates available to subscribers	-16.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$43.5M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Oncology Institute

This financial data table provides comprehensive performance metrics for Oncology Institute, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Oncology Institute generated $454M in revenue over the last twelve months.
The company achieved -$16.5M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $69.3M.
Net income over the last twelve months reached -$56.2M.

Fiscal Year Performance

In the most recent fiscal year, Oncology Institute reported $393M in total revenue.
Fiscal year EBITDA was -$50.9M.
The company maintained a gross profit margin of 13.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was -12.9%.
Net profit margin reached -16.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Oncology Institute. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Oncology Institute Stock Performance

Oncology Institute has current market cap of $322M, and EV of $395M.

Market Cap Evolution

Oncology Institute Stock Data

As of October 3, 2025, Oncology Institute's stock price is $3.

See Oncology Institute trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$395M	$322M	XXX	XXX	XXX	XXX	$-0.58

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Oncology Institute Valuation Multiples

Oncology Institute's trades at 1.0x EV/Revenue multiple, and -7.8x EV/EBITDA.

See valuation multiples for Oncology Institute and 15K+ public comps

Oncology Institute Financial Valuation Multiples

As of October 3, 2025, Oncology Institute has market cap of $322M and EV of $395M.

Equity research analysts estimate Oncology Institute's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Oncology Institute has a P/E ratio of -5.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$322M	XXX	$322M	XXX	XXX	XXX
EV (current)	$395M	XXX	$395M	XXX	XXX	XXX
EV/Revenue	0.9x	XXX	1.0x	XXX	XXX	XXX
EV/EBITDA	-24.0x	XXX	-7.8x	XXX	XXX	XXX
EV/EBIT	-9.4x	XXX	-6.6x	XXX	XXX	XXX
EV/Gross Profit	5.7x	XXX	n/a	XXX	XXX	XXX
P/E	-5.7x	XXX	-5.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-13.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Oncology Institute Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Oncology Institute Margins & Growth Rates

Oncology Institute's last 12 month revenue growth is 19%

Oncology Institute's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.

Oncology Institute's rule of 40 is -2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Oncology Institute's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Oncology Institute and other 15K+ public comps

Oncology Institute Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	19%	XXX	20%	XXX	XXX	XXX
EBITDA Margin	-4%	XXX	-13%	XXX	XXX	XXX
EBITDA Growth	-117%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-2%	XXX	6%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	45%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	29%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial